دورية أكاديمية
Endocrinological aspects of pituitary adenoma surgery in Europe
| العنوان: | Endocrinological aspects of pituitary adenoma surgery in Europe |
|---|---|
| المؤلفون: | Netuka, David, Grotenhuis, André, Foroglou, Nicolas, Zenga, Francesco, Froehlich, Sebastien, Ringel, Florian, Sampron, Nicolas, Thomas, Nick, Komarc, Martin, Kosák, Mikuláš, Májovský, Martin |
| المساهمون: | Agentura Pro Zdravotnický Výzkum České Republiky, Ministerstvo Obrany České Republiky, Progres 25 |
| المصدر: | Scientific Reports ; volume 12, issue 1 ; ISSN 2045-2322 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Multidisciplinary |
| الوصف: | Hormone-secreting adenomas are treated in many neurosurgical centers within Europe. The goal of the survey is to understand variance in practice management of pituitary tumors amongst neurosurgical centers. A list of departments performing pituitary surgery was created. The survey consisted of 58 questions. This study focuses on neurosurgical care of hormone-secreting adenomas. For analysis, the departments were divided into four subgroups: academic/non-academic, high-volume/low-volume, “mainly endoscopic/mainly microscopic practice” and geographical regions. Data from 254 departments from 34 countries were obtained. Most centers surgically treat 1–5 hormone-secreting adenomas per year. In prolactinomas this is the case in 194 centers, (76.4%), in GH-secreting adenomas: 133 centers, (52.4%), ACTH-secreting adenomas: 172 centers, (69.8%). Surgery as a primary treatment of prolactinomas is considered in 64 centers (25.2%). In 47 centers (18.8%), GH-secreting microadenomas are often treated pharmacologically first. Debulking surgery for an invasive GH-secreting adenoma in which hormonal remission is not a realistic goal of the surgery and the patient has no visual deficit surgery is always or mostly indicated in 156 centers (62.9%). Routine postoperative hydrocortisone replacement therapy is administered in 147 centers (58.6%). Our survey shows that in most centers, few hormone-secreting adenomas are treated per year. In about 25% of the centers, prolactinoma surgery may be regarded as first-line treatment; in about 20% of the centers, medical treatment is the first-line treatment for GH-secreting adenomas. Pretreatment for ACTH-secreting adenomas is routinely used in 21% of centers. This survey may serve as plea for neurosurgical care centralization of hormone-secreting adenomas. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1038/s41598-022-10300-1 |
| الإتاحة: | https://doi.org/10.1038/s41598-022-10300-1Test https://www.nature.com/articles/s41598-022-10300-1.pdfTest https://www.nature.com/articles/s41598-022-10300-1Test |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: | edsbas.C7388D4B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41598-022-10300-1 |
|---|